IMS 2023 | Novel CAR-T constructs being explored in myeloma: T-Charge platform
Adam Sperling
• 27 Sep 2023
Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the value of CAR-T therapy in relapsed/refractory (R/R) multiple myeloma, highlighting challenges with currently approved agents, including the length of time needed to manufacture these. Dr Sperling also shares some insights into a novel rapid manufacturing process being explored, known as the T-Charge platform, which allows CAR-T cells to be manufactured in 24 hours. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Novartis, Roche
